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Heart failure requiring urgent therapy represents a burgeoning health care burden. Although acute heart failure
syndromes are commonly defined as a change in chronic heart failure signs and symptoms requiring urgent
therapy, the presentation, development, and response to treatment is highly dependent on individual patient
characteristics. This heterogeneity has led to challenges in interpreting widely differing study methods, including
eligibility requirements and outcome measures. To improve interpretation of results and translate such informa-
tion to better patient care, it is essential to present an accurate description of the patient population and study
design. Based on existing recommendations and expert consensus, the authors present standardized reporting
criteria to improve interpretability of research in this challenging cohort. (J Am Coll Cardiol 2012;60:822–32)
© 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.03.072Nowak has research support relationships with Brahms and Nanosphere. Over the
past 3 years, Dr. Miller was a speaker at a CME event supported by an educational
grant from Sanofi Aventis; has had consulting relationships with The Medicines
Company and Breathquant Medical LLC; and has cardiovascular research support
relationships with Biosite Inc., Johnson & Johnson/Scios Inc., POL Biopharma,
GlaxoSmithKline, Siemens, BreathQuant Medical LLC, Heartscape TechnologiesFrom the *Vanderbilt University, Nashville, Tennessee; †University of Cincinnati,
Cincinnati, Ohio; ‡University of California-Davis, Sacramento, California; §Evan-
gelismos Hospital, Athens, Greece; Ohio State University, Columbus, Ohio;
¶University of Pennsylvania, Philadelphia, Pennsylvania; #Wayne State University,
Detroit, Michigan; **Wake Forest University, Winston-Salem, North Carolina;
††Henry Ford Hospital, Detroit, Michigan; ‡‡Northwestern University Feinberg
School of Medicine, Chicago, Illinois; §§Baylor College of Medicine, Houston,
Texas; and the  University of Hull, Kingston-upon-Hull, United Kingdom. Dr.
Inc., and Schering-Plough. Dr. Hiestand has received research funding from
Medtronic Inc., Biosite Inc., Inovise Medical Inc., Heartscape International, Nano-
r823JACC Vol. 60, No. 9, 2012 Storrow et al.
August 28, 2012:822–32 The AHFS Reporting CriteriaThe emergent evaluation and management of patients with
possible acute heart failure syndromes (AHFS) remains a
significant challenge. Unlike major advances in the assess-
ment and treatment of patients with acute coronary syn-
dromes, the diagnostic tools and therapeutic options for
patients presenting with AHFS have changed little for
decades (1), and the complexity of AHFS has led to a practice of
isk aversion and extremely high hospitalization rates (2–5). These
difficulties, as well as the increasing prevalence of heart failure,
have placed an enormous burden on health care resources world-
wide (2).
The cohort of AHFS patients is diverse. Although they
might be commonly defined as patients with a gradual or
rapid change in chronic heart failure signs and symptoms
resulting in a need for urgent or unscheduled therapy
(4,6,7), the development, presentation, and response to
treatment is dependent on each individual’s pathophysiol-
ogy and comorbidities. Researchers have studied a wide
range of patient populations with different eligibility criteria
and medical histories and using divergent outcome mea-
sures. To better interpret available research in the light of
this study-related heterogeneity and to improve the level of
evidence supporting the acute evaluation and management
of the AHFS patient, it is critical to present a thorough
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2012, accepted March 7, 2012.description of the patient popu-
lation evaluated. Methods of pa-
tient selection, demographics
and medical history of eligible
patients, intervention or evalua-
tion protocols, outcome mea-
sures, and time intervals for mea-
surements must be consistently
reported. Based on existing rec-
ommendations and expert con-
sensus, these guidelines aim to
provide investigators a frame-
work for reporting studies of pa-
tients with possible AHFS. By
providing these standardized
reporting criteria, we hope to
improve the interpretability of
research in this challenging pa-
tient cohort and thus to im-
prove patient care through bet-
ter application of evidence-based medicine.
Development of Criteria
A working group of the Emergency Management and
Research Group in Acute Heart Failure met in May 2007 to
begin developing the reporting guidelines. Eight areas of
importance were identified and assigned to working group mem-
bers to develop initial recommendations based on existing guide-
lines:
1. Screening and recruitment
2. Demographics
3. Previous cardiac diagnosis, risk factors, medical history
4. Acute presentation (clinical characteristics)
5. Test reporting and observation care
6. Patient course including response to treatment
7. Outcomes
8. Follow-up period
The initial recommendations were modified and circu-
lated to working group members before in-person meetings
in October 2007, May 2008, October 2008, and May 2009.
At these meetings, each proposed reporting element was
discussed for incorporation as a core measure, supplemental
measure, or dropped from further consideration.
The working draft was then distributed among the
various stakeholders, including other members of Emer-
gency Management and Research Group in Acute Heart
Failure, for expansion and revision throughout 2010 and
early 2011. Representatives of the Society of Academic
Emergency Medicine, the American College of Emergency
Physicians, the American Heart Association, the American
College of Cardiology, the Heart Failure Society of Amer-
ica, the Society of Chest Pain Centers, and the Working
Group of Acute Cardiac Care of the European Society of
Cardiology were given the opportunity to review and revise
Abbreviations
and Acronyms
AHFS  acute heart failure
syndrome
BNP  B-type natriuretic
peptide
CAD  coronary artery
disease
ECG  electrocardiogram
ED  emergency
department
GFR  glomerular filtration
rate
ICD  implantable
cardioverter-defibrillator
MI  myocardial infarction
NT-proBNP  N-terminal
pro–BNPthe reporting guidelines. Once consensus was achieved, the
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ing Suspected Acute Heart Failure Syndromes in the
Emergency Department were finalized for publication.
The guidelines have been endorsed by Society of Aca-
demic Emergency Medicine, American College of Emer-
gency Physicians, American Heart Association, Society
of Chest Pain Centers, and the Working Group on Acute
Cardiac Care of the European Society of Cardiology.
Structure and Suggestions for
Use of This Document
These guidelines emphasize the minimum information that
should be reported and additional information that would
be of benefit to report when presenting studies of the
evaluation and management of AHFS. The structure is
similar to recently introduced reporting guidelines for pos-
sible acute coronary syndromes (8). Where available, we
have used the definition of data elements as provided by the
American College of Cardiology, American Heart Associ-
ation, European Society of Cardiology, Heart Failure Soci-
ety of America, Society of Chest Pain Centers, or World
Heart Federation (9–18). Where definitions do not exist or
are insufficient to clarify ambiguity in reporting, new defi-
nitions have been provided.
Throughout the document, bolded items are identified as
core components (Table 1), and these should be reported in
all studies of the evaluation and management of AHFS.
Supplemental items are not bolded but should be reported
whenever possible. Core components represent the minimal
amount of information necessary to compare and contrast
studies and can be used by investigators to guide data
collection and presentation of results. As well as facilitating
the design of studies, peer reviewers evaluating manuscripts
for publication may use these criteria to determine whether
sufficient information is reported to allow readers to place
the study in appropriate context and compare results with
those of other publications. Clinicians may find it helpful to
use the core criteria to determine whether reported popu-
lations are similar to the patients they treat and thus
facilitate an evidence-based medicine approach to the acute
evaluation and management of AHFS. Reporting AHFS
studies in accordance with the guidelines will facilitate
systematic review and meta-analysis, maximizing the impact
of research on clinical practice.
1. Screening and Recruitment
Patients with AHFS are a heterogeneous population.
The performance of diagnostic and prognostic interven-
tions is dependent on the severity, prevalence, and
pathophysiology of the disease in the study population,
as well as comorbid conditions or alternative diagnoses.
The methods of screening and recruiting subjects and
study inclusion and exclusion criteria are key factors
affecting these parameters and thus should be reported.
1.1. Specific ages for inclusion and exclusion1.2. Procedure for identifying population to be
screened
1.2.1. Signs, symptoms, or other criteria to prompt
screening
1.2.2. Days and times of screening
1.2.3. Location of screening
1.3. Method of screening
1.3.1. By symptoms at presentation
1.3.1.1. The specific symptoms used for inclu-
sion and exclusion
1.3.1.2. The time of onset and duration of
symptoms used for inclusion and
exclusion
1.3.2. By emergency department (ED) discharge/
hospital admission diagnosis
1.3.3. By hospital discharge diagnosis
1.3.4. By diagnostic testing
1.3.4.1. Use of diagnostic testing (e.g., ordering
echocardiography)
1.3.4.2. Results of diagnostic testing (e.g., ele-
vated B-type natriuretic peptide [BNP])
1.3.5. By administration of medications (e.g., nitro-
glycerin, furosemide)
1.3.6. By pre-specified criteria (e.g., Framingham
Criteria)
1.4. Account for patients screened and included and
excluded from the study
1.4.1. Flow diagram to account for all patients
1.4.2. Report total ED census for participating in-
stitution(s)
1.4.3. Report ED volume of potential patients (e.g.,
total number of patients evaluated for AHFS)
1.4.4. Report volume of potential patients screened
2. Demographics
A description of the patients studied is important to
understand the relevance of the study to specific popu-
lations to allow comparisons of different patient popula-
tions and for risk adjustments.
2.1. Sex
2.2. Age
2.3. Race, including method of determination (19):
2.3.1. American Indian or Alaska Native
2.3.2. Asian
2.3.3. Black or African American
2.3.4. African descendent
2.3.5. Native Hawaiian or other Pacific Islander
2.3.6. White
2.3.7. Other
2.3.8. Mixed race
2.4. Ethnicity
2.4.1 Hispanic
2.4.2. Non-Hispanic
2.5. Insurance status (refers to the primary payor)2.5.1. Private refers to all private medical insurance.
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payment for medical bills.
2.5.3. Other refers to local, regional, or national
government insurance program, charity, tax
levy, or other source of payment
2.5.4. In the United States, differentiate Medicare
from Medicaid
2.6. Mode of transport (means by which the patient
arrived at the ED)
2.6.1. Self/family
2.6.2. Ground ambulance (basic, intermediate, or
advanced)
2.6.3. Air ambulance
2.6.4. Other
2.7. Source of patients (place where patient resides at
time of acute presentation)
2.7.1. Home
2.7.2. Other hospital facility
2.7.3. Extended care facility
2.7.4. Jail or prison
2.7.5. Other
. Previous cardiac diagnosis, risk factors, and medical
history
In the acute care setting, physicians frequently do not
have access to detailed medical records and, therefore,
must typically rely on patient self-report. In studies of
AHFS conducted in the acute care setting, it is accept-
able to rely on patient self-report of cardiac risk factors.
However, the investigators must report the method of
evaluation.
3.1. Hypertension
3.2. Family history of early coronary artery disease
(CAD) (acute myocardial infarction [MI], angina,
or sudden cardiac death in a first-degree relative,
male younger than 55 years of age, female younger
than 65 years of age)
3.3. Diabetes mellitus (regardless of duration of disease
or use of specific medications)
3.3.1. Type of diabetes mellitus treatment (diet, oral
agents, insulin alone, or insulin with oral
agents)
3.3.2. Year of onset or first diagnosis
3.4. Smoking
3.4.1. Current (within 1 month)
3.4.2. Recent (stopped between 1 month and 1 year
before enrollment)
3.4.3. Former (stopped 1 year before enrollment)
3.4.4. Never smoker
3.5. Hypercholesterolemia or hyperlipidemia
3.6. Drug and alcohol use
3.6.1. Amount and duration
3.6.2. Results of toxicology testing
3.6.3. Current (within 1 month)
3.6.4. Recent (stopped between 1 month and 1 yearbefore enrollment)3.6.5. Former (stopped 1 year before enrollment)
3.7. Renal Insufficiency
3.7.1. Elevated creatinine
3.7.2. Reduced creatinine clearance or glomerular
filtration rate (GFR); investigators must identify
the method used to calculate these variables
3.7.3. Albuminuria
3.8. Presence of obesity
3.8.1. Body mass index
3.9. AMI. If the previous AMI is confirmed through
medical record review and meets the European
Society of Cardiology/American College of Cardiology/
American Heart Association/World Heart Federation
criteria (16), this should be noted. If the history of
AMI cannot be confirmed to meet these criteria, then
it should be recorded as “reported history of AMI.” If
an alternative definition is used, this should be given.
3.10. Known cardiovascular disease
3.10.1. Heart failure (any previous episodes). If the
presence of heart failure is documented in the
medical record, this should be noted. Other-
wise, it should be reported as “self-reported
history of heart failure.”
3.10.1.1. Etiology of heart failure (if known)
3.10.1.2. Preserved or reduced systolic function
and definition used
3.10.2. CAD. If the presence of CAD is docu-
mented in the medical record through ob-
jective criteria such as cardiac catheteriza-
tion with significant stenosis, demonstrated
electrocardiographic changes, perfusion de-
fects, or wall motion abnormalities on exercise
or pharmacological imaging studies, this should
be noted (11). Otherwise, it should be recorded
as “self-reported history of CAD.”
3.10.2.1. Revascularization (percutaneous coro-
nary intervention, coronary artery by-
pass graft)
3.10.2.1.1 Type, number of grafts or
stented vessels, year
3.10.3. Ventricular arrhythmias
3.10.3.1. Ventricular tachycardia resulting in
symptoms or acute intervention
3.10.3.2. Ventricular fibrillation
3.10.4. Cardiac arrest
3.10.5. Atrial arrhythmias
3.10.5.1. Atrial fibrillation or flutter (20)
3.10.5.1.1. First detected
3.10.5.1.2. Paroxsymal
3.10.5.1.3. Persistent
3.10.6. Peripheral vascular disease
3.10.6.1. Peripheral arterial disease
3.10.6.2. Venous thromboembolic disease
3.10.7. Cerebrovascular events
3.10.8. Automatic internal cardiac defibrillator (ICD)3.10.8.1. ICD only
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brillator (cardiac resynchronization
therapy  ICD)
3.10.9. Pacemaker
3.10.9.1. Single chamber, dual chamber
3.10.9.2. Biventricular
3.10.10. Valvular disease
3.10.10.1. Native valve
3.10.10.2. Prosthetic valve
3.11. Previous objective assessments of cardiac function
3.11.1. Previous ejection fraction
3.11.1.1. Time interval from testing to ED visit
3.11.1.2. Method used to assess ejection frac-
tion (e.g., echocardiography, catheteriza-
tion, nuclear study)
3.11.2. Most recent known ejection fraction
3.11.3. Presence or absence of diastolic dysfunction,
ventricular hypertrophy, regional wall motion
abnormalities, valvular disease
3.11.4. Baseline (well or dry weight) BNP or
N-terminal pro–BNP (NT-proBNP) values
3.12. Pulmonary disease
3.12.1. Asthma
3.12.2. Chronic obstructive pulmonary disease
3.12.3. Other
3.13. Home treatment
3.13.1. Current medications and definition used for
current
3.13.1.1. Diuretics
3.13.1.2. Vasodilators (e.g., nitroglycerin,
hydralazine)
3.13.1.3. Angiotensin-converting enzyme
inhibitors
3.13.1.4. Angiotensin-receptor blockers
3.13.1.5. Inotropes
3.13.1.6. Aspirin
3.13.1.7. Adenosine diphosphate receptor
inhibitors
3.13.1.8. Beta-blockers
3.13.1.9. Calcium channel blockers
3.13.1.9.1. Amlodipine
3.13.1.9.2. Other calcium channel
blockers
3.13.1.10. Oral anticoagulants
3.13.1.10.1. Coumadin
3.13.1.10.2. Others
3.13.1.11 Aldosterone antagonists
3.13.1.12. Digoxin
3.13.1.13. Alpha antagonists
3.13.2 Contraindications to recommended treatments
3.13.3. Other home treatments
. Acute presentation
The vast majority of patients with AHFS will have
dyspnea as their chief symptom. A clear yet concise
description of the degree and magnitude of breathless-ness is therefore requisite for any investigation of AHFS,
particularly those that involve stratification by severity of
presentation or cross-population comparison. Quantifi-
cation of symptom severity using tools such as the New
York Heart Association classification system or relative
Likert scales (21,22) is considered useful, but their
validity may be limited by the subjectivity inherent to
patient self-assessment. The recently proposed axis
model should be taken into consideration, however its
utility remains to be determined (23).
4.1. Dyspnea
4.1.1. Onset
4.1.1.1. Abrupt
4.1.1.2. Gradual
4.1.2. Character
4.1.2.1. Exertional only (mild)
4.1.2.2. At rest (moderate)
4.1.2.2.1. Without orthopnea
4.1.2.2.2. With orthopnea
4.1.2.2.3. Paroxysmal nocturnal
4.1.2.3. Respiratory distress (severe)
4.1.2.3.1. Needs immediate noninva-
sive ventilatory support
4.1.2.4. Respiratory failure
4.1.2.4.1. Needs immediate intubation
4.1.3. Comparison with baseline
4.1.4. Respiratory rate
4.1.5. Oxygen saturation
4.1.5.1. Indicate amount of supplemental ox-
ygen currently administered
4.1.6. Signs of pulmonary congestion
4.1.6.1. Rales
4.1.6.1.1. Basilar only
4.1.6.1.2. Less than one-half lung field
4.1.6.1.3. More than one-half lung field
4.1.6.2. Wheeze
4.1.6.3. Accessory muscle use
4.2. Other signs and symptoms
4.2.1. Murmur (location, timing, and intensity)
4.2.2. Gallop (S3, S4)
4.2.2.1. Auscultation
4.2.2.2. Phonocardiography
4.2.3. Elevated jugular venous pressure
4.2.4. Peripheral edema
4.2.5. Hepatic congestion
4.2.6. Ascites
4.2.7. Anasarca
4.2.8. Weight at baseline
4.2.9. Weight gain
4.2.10. Height (for determination of GFR)
4.2.11. Fatigue
4.2.12. Syncope
4.2.13. Chest pain
4.2.14. Palpitations
4.3. Hemodynamic status. Hemodynamic status on
presentation is a critical determinant of AHFS
827JACC Vol. 60, No. 9, 2012 Storrow et al.
August 28, 2012:822–32 The AHFS Reporting Criteriamanagement (24,25) and has significant implica-
tions for clinical trial design. Uniform reporting of
relevant parameters, therefore, is essential. Blood
pressure is a particularly important variable to in-
clude and should be presented as needed to best
characterize patient cohorts (7,26).
4.3.1. Blood pressure
4.3.1.1. Continuous integers
4.3.1.1.1. Systolic
4.3.1.1.2. Diastolic
4.3.1.2. Categorical (report cutoffs used)
4.3.1.2.1. Hypertensive
4.3.1.2.2. Normotensive
4.3.1.2.3. Hypotensive
4.3.1.2.4. Cardiogenic shock (hypo-
tension with signs of
hypoperfusion)
4.3.2. Heart rate
4.3.3. Other parameters (report if available along
with method [invasive or noninvasive] by
which they were obtained)
4.3.3.1. Cardiac index/output
4.3.3.2. Systemic vascular resistance
4.3.3.3. Stroke volume
4.3.3.4. Pulmonary capillary wedge pressure
4.4. Precipitating factors. These are the factors that are
considered causative for the acute event rather than
contributory to the underlying etiology of heart
failure.
4.4.1. Uncontrolled hypertension
4.4.2. Acute cardiac ischemia/infarct
4.4.3. Arrhythmia
4.4.4. Noncompliance (e.g., medication, diet)
4.4.5. Toxicity (e.g., cocaine, amphetamines)
4.4.6. Acute valve problems (e.g., acute mitral
regurgitation)
4.4.7. Myocarditis
4.4.8. High-output states (e.g., thiamine deficiency,
thyrotoxicosis, sepsis, Paget’s disease, severe
anemia)
4.4.9. Systemic infections (e.g., pneumonia, urinary
tract)
4.4.10. Pulmonary embolism
4.4.11 Development of comorbid states (e.g., renal
failure, anemia, hypothyroidism)
5. Test Reporting
The tests used to evaluate patients with AHFS in the
acute setting typically include the electrocardiogram
(ECG), chest radiographs, and laboratory assays. Each of
these should be reported with sufficient detail to enable
accurate interpretation of the results. The lab result
section (5.3) is meant to be an overview for both
diagnostic and therapeutic studies. More detailed recom-
mendations about biomarker reporting are available else-
where (27–30).5.1. ECG
5.1.1. Person(s) interpreting the ECGs
5.1.2. Timing of ECG relative to presentation
5.1.2.1. Presenting ECG
5.1.2.2. Out-of-hospital ECG
5.1.2.3. Serial in-hospital ECGs
5.1.3. Findings suggestive of acute coronary syndrome
5.1.3.1. Rate
5.1.3.2. Rhythm
5.1.3.3. Overall categorization of the ECG (31)
5.1.3.3.1. Normal
5.1.3.3.2. Nonspecific ST-T wave
changes
5.1.3.3.3. Abnormal but not diagnos-
tic of ischemia
5.1.3.3.4. Infarction or ischemia known
to be old
5.1.3.3.5. Ischemia or infarction not
known to be old
5.1.3.3.6. Consistent with AMI (ST-
segment elevation or new
left bundle branch block)
5.1.4. Dynamic ECG analysis
5.1.5. Presence of left bundle branch block
5.2. Chest radiograph
5.2.1. Procedure used for imaging
5.2.1.1. Anteroposterior (portable) technique
5.2.1.2. Posteroanterior and lateral technique
5.2.2. Person(s) interpreting the chest radiograph
5.2.3. Findings on the chest radiograph
5.2.3.1. Cardiomegaly
5.2.3.2. Pulmonary vascular redistribution
5.2.3.2.1. Mild
5.2.3.2.2. Moderate (e.g., Kerley B
lines, fluid in fissure)
5.2.3.2.3. Severe (pulmonary edema)
5.2.3.3. Pleural effusion
5.2.3.4. Other major abnormality (e.g., pneu-
monia, mass)
5.3. Lab results
5.3.1. Timing of the lab specimen
5.3.1.1. Relative to symptom onset
5.3.1.2. Relative to clinical characteristics
5.3.2. Serum chemistry and blood analysis results,
including the units of measurement
5.3.2.1. Blood urea nitrogen or urea
5.3.2.2. Creatinine
5.3.2.3. GFR
5.3.2.4. Sodium
5.3.2.5. Hemoglobin
5.3.2.6. Natriuretic peptides
5.3.2.6.1. Manufacturer name
5.3.2.6.2. BNP
5.3.2.6.3. NT-proBNP5.3.2.7. Cardiac biomarkers
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normal) and manufacturer
5.3.2.7.2. Established cutoffs for nor-
mal values and method by
which they were derived
5.3.2.8. Other AHFS biomarkers may be
considered
5.3.2.8.1. Midregional pro-atrial natri-
uretic peptide, adrenomedullin
5.3.3. Specimen collection and handling procedures
5.3.3.1. Detailed methods of sample handling
and compliance with manufacturer
recommendations
5.3.3.2. Phlebotomy tubes used (reagent),
centrifugation, etc.
5.3.3.3. Assay performed individually or batched,
run at time of blood draw or delayed
5.3.3.4. Location (e.g., at bedside, ED stat
laboratory, offsite research laboratory)
5.3.3.5. Storage (e.g., sample frozen within
how many hours of draw, flash frozen
on liquid nitrogen, freezing tempera-
ture, length of time frozen)
5.3.4. Marker performance relative to defined out-
comes. This is a core requirement if the
primary objective of the investigation is
assessment of marker performance; other-
wise, it is a supplemental criterion.
5.3.4.1. Sensitivity, specificity, positive predic-
tive value, negative predictive value, and
likelihood ratios with 95% confidence
intervals
5.3.4.2. Receiver-operating characteristic curve
data
5.3.4.2.1. Optimal operating point and
how defined
5.3.4.2.2. Interval likelihood ratios
5.3.5. Relevant confounders for the assays being
used. This is a core requirement if the
primary objective of the investigation is
assessment of marker performance; other-
wise, it is a supplemental criterion.
5.3.5.1. Proportion of patients with renal in-
sufficiency
5.3.5.2. Body mass index for natriuretic pep-
tide testing
6. Patient Course
Patient course can be quite variable for patients present-
ing with AHFS. Medications administered as well as the
timing of interventions may have a significant impact on
patient course and disposition. Medications and inter-
ventions should be reported according to whether they
were given early in the patient course or as secondary
treatment after initial therapy had not produced an
adequate response. Further categorization is also neededto delineate whether the medication was given as a
primary treatment or a secondary (preventive) measure.
6.1. ED and hospital course
6.1.1. ED disposition
6.1.1.1. Discharge
6.1.1.2. Observation unit admission
6.1.1.3. Inpatient admission
6.1.1.4. Left ED against medical advice
6.1.1.5. Died in ED
6.1.1.6. Transferred
6.1.2. Observation unit management
6.1.2.1. System
6.1.2.1.1. Virtual unit or defined space
6.1.2.1.2. Level of monitoring (i.e.,
telemetry)
6.1.2.1.3. Number of beds
6.1.2.1.4. Eligibility criteria for unit
admission
6.1.2.1.5. Heart failure specific or
general
6.1.2.2. Personnel
6.1.2.2.1. The training characteristics
of personnel primarily re-
sponsible for the patient un-
dergoing observation care
6.1.2.3. Treatment protocols
6.1.2.3.1. Therapeutic protocols or al-
gorithms in use for patients
undergoing observation care
6.1.2.3.2. Rate of protocol compliance
6.1.2.4. The length of time under observation
status
6.1.2.5. Disposition
6.1.2.5.1. Home
6.1.2.5.1.1. Discharge cri-
teria, including
any consultation
requirements
6.1.2.5.2. Inpatient admission
6.1.2.5.3. Left observation unit against
medical advice
6.1.2.5.4. Died in observation unit
6.1.3. Inpatient admission
6.1.3.1. Intensive care unit/cardiac care unit
6.1.3.2. Telemetry
6.1.3.3. Unmonitored floor bed
6.1.3.4. Transferred
6.1.3.2. Inpatient disposition
6.1.3.2.1. Home
6.1.3.2.2. Died in hospital
6.1.3.2.3. Hospice
6.1.3.2.4. Transferred to another hospital
6.1.3.2.5. Extended care facility
6.2. Therapeutics and interventions
6.2.1. Pharmacological therapeutics6.2.1.1. Aspirin
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6.2.1.2.1. Nitroglycerin and route (intra-
venous, topical, sublingual)
6.2.1.2.2. Nitroprusside
6.2.1.2.3. Nesiritide
6.2.1.2.4. Phenylephrine
6.2.1.2.5. Norepinephrine
6.2.1.2.6. Epinephrine
6.2.1.2.7. Dopamine
6.2.1.3. Inotropic agents
6.2.1.3.1. Dobutamine
6.2.1.3.2. Milrinone
6.2.1.3.3. Levosimendan
6.2.1.4. Diuretics
6.2.1.4.1. Name of diuretic
6.2.1.4.2. Dose
6.2.1.4.3. Mode of administration (oral,
intravenous bolus, or con-
tinuous infusion)
6.2.1.5. Beta-blockers
6.2.1.6. Angiotensin-converting enzyme
inhibitors
6.2.1.7. Angiotensin receptor blockers
6.2.1.8. Aldosterone antagonists
6.2.1.9. Morphine
6.2.1.10. Atropine
6.2.1.11. Antiarrhythmic (e.g., adenosine, ami-
odarone)
6.2.1.12. Antithrombins (e.g., unfractionated
heparin, low molecular weight hepa-
rin, direct thrombin inhibitors)
6.2.1.13. Others
6.2.2. Nonpharmacological therapeutics
6.2.3. Interventions
6.2.3.1. Primary
6.2.3.2. Secondary/preventive
6.2.3.3. Noninvasive ventilation (continuous
positive airway pressure/bilevel posi-
tive airway pressure)
6.2.3.4. Intubation
6.2.3.5. Electrical cardioversion
6.2.3.6. Defibrillation
6.2.3.7. Right heart catheter, both as a 1-time
procedure to obtain diagnostic data
and a pulmonary artery catheter to
follow response to therapy
6.2.3.8. Left heart catheterization
6.2.3.9. Single-chamber pacemaker
6.2.3.10. Biventricular pacemaker
6.2.3.11. Implantable cardioverter-defibrillator
6.2.3.12. Percutaneous coronary intervention
6.2.3.13. Balloon pump
6.2.3.14. Ultrafiltration
6.2.3.15. Percutaneous cardiopulmonary support
6.2.3.16. Ventricular assist device
6.2.3.17. Transplantation6.2.3.18. Others
6.2.4. Timing of therapy or intervention relative to
presentation
6.2.4.1. Pre-hospital
6.2.4.2. Early (within first 12 to 24 h)
6.2.4.3. Late (after first 24 h)
6.2.5. Route of administration of therapy
6.2.5.1. Oral
6.2.5.2. Sublingual
6.2.5.3. Intravenous
6.2.5.4. Intramuscular/subcutaneous
6.2.6. Endotracheal tube
6.2.7. Dose of therapy
6.3. Response to treatment
6.3.1. Total urinary output
6.3.2. Weight change during hospitalization
6.3.3. Total input/output during hospitalization
6.3.4. Laboratory values before discharge
6.3.4.1. Blood urea nitrogen
6.3.4.2. Creatinine
6.3.4.3. GFR
6.3.4.4. Sodium
6.3.4.5. Potassium
6.3.4.6. BNP/NT-proBNP
6.3.4.7. Hemoglobin
6.3.5. Hemodynamic values before discharge
6.3.5.1. Blood pressure (systolic and diastolic)
6.3.5.2. Heart rate
6.3.6. Respiratory status before discharge
6.3.6.1. Respiratory rate
6.3.6.2. Oxygen saturation including amount
of supplemental oxygen
6.3.7. Jugular venous pressure before discharge
7. Outcomes
Hospitalization for AHFS is a significant marker for
post-discharge events (i.e., rehospitalization or mortal-
ity). However, very few studies have been conducted that
looked at short-term outcomes based on acute manage-
ment. Development and establishment of short-term
outcome goals or targets is a current area of investiga-
tional research, balancing the needs of clinicians, inves-
tigators, and regulatory agencies. For studies of the
management and evaluation of AHFS, therefore, the
definition of outcomes appropriate to the study’s purpose
should be reported.
7.1. Safety and efficacy endpoints
7.1.1. Mortality
7.1.1.1. Days from presentation (e.g., 5 days,
7 days, 30 days, 180 days)
7.1.2. Morbidity
7.1.2.1. Worsening heart failure (as defined
for the study)
7.1.2.2. Days alive and out of hospital
7.1.3. Resource utilization7.1.3.1. Lengths of stay
Continued in next column
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7.1.3.3. Recidivism
7.2. Organ protection/preservation/improvement
7.2.1. Cardiac
7.2.1.1. Biomarkers
7.2.1.2. ECG
7.2.1.3. Echocardiographic indices
7.2.1.4. Hemodynamic (specify invasive or
noninvasive)
7.2.1.5. Serious arrhythmia (atrial fibrillation/
flutter, ventricular tachycardia, ven-
tricular fibrillation)
7.2.2. Renal
7.2.2.1. Blood urea nitrogen
7.2.2.2. Creatinine
7.2.2.3. Creatinine clearance or GFR (specify
method of calculation if estimated)
7.2.2.4. Novel biomarkers
7.2.2.5. Other
7.2.3. Stroke
7.2.3.1. Hemorrhagic
7.2.3.2. Nonhemorrhagic
7.3. Interventions
7.3.1. Pharmacological
7.3.1.1. Need for rescue therapy (define)
7.3.2. Surgical
ContinuedTable 1 Continued
6. Patient course
6.1. ED and hospital course
6.1.1. ED disposition
6.1.2. Observation unit management
6.1.2.5. Disposition
6.1.3. Inpatient admission
6.1.3.2. Inpatient disposition
6.2. Therapeutics and interventions
6.2.1. Pharmacological therapeutics
6.2.2. Nonpharmacological therapeutics
6.2.3. Interventions
6.2.3.1. Primary
6.2.3.2. Secondary/preventive
6.3. Response to treatment
6.3.8. Therapeutics given
6.3.9. Interventions
6.3.9.1. Primary
6.3.9.2. Secondary/preventive
6.4. Response to treatment
7. Outcomes
7.1. Safety and efficacy endpoints
7.1.1. Mortality
7.1.2. Morbidity
8. Follow-up
8.1. Duration of follow-up
8.2. Clinical follow-up and timing
8.3. Research follow-up
ECG  electrocardiogram; ED  emergency department.Core ComponentsTable 1 Core Components
1. Screening and recruitment
1.1. Specific ages for inclusion and exclusion
1.2. Procedure for identifying population to be screened
1.3. Method of screening
1.4. Account for patients screened and included in and excluded
from the study
2. Demographics
2.1. Sex
2.2. Age
2.3. Race
3. Previous cardiac diagnosis, risk factors, and medical history
3.1. Hypertension
3.3. Diabetes mellitus
3.4. Smoking
3.5. Hypercholesterolemia or hyperlipidemia
3.9. Acute myocardial infarction
3.10. Known cardiovascular disease
3.10.1. Heart failure
3.10.1.1. Etiology of heart failure (if known)
3.10.1.2. Preserved or reduced systolic function and definition used
3.10.2. Coronary artery disease.
3.11. Previous objective evaluations for heart failure
3.11.1. Previous ejection fraction or current ejection fraction
3.11.1.2. Method used to assess ejection fraction (e.g., echocardiography,
catheterization, nuclear study)
3.13. Home treatment
4. Acute presentation
4.1. Dyspnea
4.1.4. Respiratory rate
4.1.5. Oxygen saturation
4.3. Hemodynamic status
4.3.1. Blood pressure
4.3.2. Heart rate
4.4. Precipitating factors
5. Test reporting
5.1. ECG
5.1.1. Person(s) interpreting the ECGs
5.1.2. Timing of the ECG relative to presentation
5.1.3. Findings suggestive of acute coronary syndrome
5.2. Chest radiograph
5.2.1. Procedure used for imaging
5.2.2. Person(s) interpreting the chest radiograph
5.2.3. Findings on the chest radiograph
5.3. Lab results
5.3.1. Timing of the lab specimen
5.3.2. Serum chemistry and blood analysis results, including the units of
measurement
5.3.3. Specimen collection and handling procedures
5.3.4. Marker performance relative to defined outcomes. This is a core
requirement if the primary objective of the investigation is
assessment of marker performance; otherwise, it is a supplemental
criterion.
5.3.5. Relevant confounders for the assays being used. This is a core
requirement if the primary objective of the investigation is
assessment of marker performance; otherwise, it is a supplemental
criterion.7.3.3. Procedural
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invasive ventilation)
7.4. Symptoms and signs (distinguish between physician
assessed and patient assessed)
7.4.1. Dyspnea
7.4.2. Jugular venous pressure
7.4.3. Rales
7.4.4. Edema
7.4.5. Other
7.5. Quality of life
7.5.1. Quality of life questionnaires (e.g., Kansas
City Cardiomyopathy Questionnaire)
7.6. Response to therapy
7.6.1. Body weight
7.6.2. Urine output
7.6.3. Functional capacity (e.g., 6-min walk test)
7.6.4. Other
7.7. Composite endpoints: each component needs to be
specifically defined
7.7.1. Global rank: events prioritized by importance
(e.g., death  rehospitalization  biomarker
elevation); this method provides an opportu-
nity for more subjects to experience an “endpoint”
7.7.2. Breakdown of individual endpoints of com-
posite measure
. Follow-up
There are limited data available regarding a recom-
mended time to follow-up after an ED visit or hospitalization
for AHFS (13,32–34). Access to follow-up care may vary
depending on several factors including availability of heart
failure specialty or primary care clinics and the patient’s
insurance status. Poor outpatient follow-up may exert consid-
erable confounding on research outcomes. Patients with an
inability to obtain appropriate medications or clinical follow-up
may experience adverse events independent of the research
intervention being applied. Both clinical and research
follow-up should therefore be reported.
8.1. Duration of follow-up
8.1.1. Start point of follow-up period
8.1.1.1. Presentation
8.1.1.2. In-hospital/treatment events
8.1.1.3. Discharge
8.2. Clinical follow-up and timing
8.2.1. Access to and attendance at care providers
during the follow-up period
8.2.1.1. Primary care
8.2.1.2. Cardiologist
8.2.1.3. Heart failure specialty clinic
8.3. Research follow-up
8.3.1. Methodology
8.3.1.1. Telephone or in person
8.3.1.2. Patient or proxy
8.3.1.3. Use of medical record review
8.3.1.3.1. Primary follow-up method
8.3.1.3.2. Supplementary to contact8.3.1.3.3. Confirmatory of reported
events
8.3.1.4. Insurance/claims data
8.3.1.5. National registry/Social Security Death
Index
8.3.2. Proportion lost to follow-up
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